Automated Analysis of High-Throughput Protein Stability For Antibody Developability Assessment

October 21, 2025

High‑throughput biophysical assays such as DLS and nanoDSF generate vast datasets that are essential for early antibody developability assessment - but difficult to analyze at scale. This poster demonstrates how Genedata Screener automates the analysis of high‑throughput protein stability data and unifies results across assays to deliver a more predictive, efficient approach to biologics development.

Learn how integrating stability readouts with modern antibody informatics, sequence‑structural analysis software, and developability screening software enables rapid identification of liabilities across antibody and ADC development programs. The resource highlights how advanced AI-powered drug discovery technologies - including AI-driven developability prediction software, generative AI protein design software, and in silico screening software - can be combined with Genedata’s developability assessment platform to streamline decision‑making and reduce manual data review.

Download the poster to see how Genedata’s enterprise‑scale platform accelerates drug discovery and development and strengthens the role of AI in drug development by transforming raw stability data into actionable developability insights.